Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test
HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy
Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), and that it is now available for sale within Canada.
REASONS TO BELIEVE
THE RIGHT INTENTION
Entheon’s founders share a direct and personal understanding of the endless suffering and loss of human potential that comes with unsuccessful attempts to treat a disorder that has proven highly resistant to existing therapeutic models.
THE RIGHT PARTNERS
Entheon is collaborating with leaders in the psychedelic medicine space, in Canada and around the world. The meaningful inputs of our research and academic partners are validating our process, guiding our clinical trials and optimising the safety and efficacy of our product design.
THE RIGHT MOLECULE
Well tolerated with few adverse effects, pure DMT is the ideal molecule for advancing new models of psychedelic-assisted therapy. DMT is unique among hallucinogens in that it is endogenous in the human body. While other drugs in the class produce intense effects that last up to 12 hours, the effects of DMT are more gradual, less jarring and much shorter in duration.
THE RIGHT TECHNOLOGY
Our unique proposed delivery system titrates DMT into the body allowing for a gradual, more comfortable transition to the psychedelic state. The ability to control the duration and intensity of DMT’s effects, along with the ability to rapidly end the experience, will allow clinicians to provide the therapeutic effects of hallucinogens in a safer, more controlled and patient-specific manner.
THE RIGHT PATIENT EXPERIENCE
Our nuanced, individualized approach considers every aspect of the patient journey, including how the individual is informed and prepared, the comfort and ambiance of their treatment environment, and, following the psychedelic event, how they integrate the experience through talk therapy and post-care.
Management & Board
Chief Executive Officer
Timothy Ko has a broad background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology. Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health system, and through his exposure to psychedelics which he credits with saving his life.
Brandon Schwabe, CPA, CGA
Chief Financial Officer
Brandon is a Chartered Professional Accountant (CPA, CGA) who holds a Bachelor of Technology in Accounting degree with distinction from BCIT, and has completed the Canadian Securities Course (CSC) from the Canadian Securities Institute.
Drawing on more than a decade of progressive experience guiding financial decisions and delivering solutions for companies, Brandon has extensive experience with private enterprises engaged in large capital projects, understanding the unique challenges they face.
Andrew Hegle, PhD
Director of Operations & Chief Science Officer
Dr. Andrew Hegle has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. He has a background in molecular biology and biochemistry and has published research investigating the role of membrane receptor proteins in physiology, behavior and disease.
Andrew’s main professional focus has been in the creation and management of laboratory operations, and has held executive and operational management positions at several biotechnology companies, and was a cofounder of both Cannevert Therapeutics and Canalytic Laboratories in Vancouver.
Dr. Brian Jahns
Chief Business Officer
Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with third parties, including regulatory authorities. Importantly, Dr. Jahns will also work to develop a commercialization and post-market strategy for Entheon’s therapeutic protocols, while developing and advancing other related products, services, and initiatives of the company.
Yaron has 15 years of experience in Life Sciences innovation. Having led efforts in product development, regulatory compliance, and operations, Yaron has worked within start-ups as well as having consulted for them.
Yaron has navigated the US, European, Israeli and Australian regulatory agencies including the registration of manufacturing facilities in the US, Central America, Israel and Australia to Good Manufacturing Practice levels. Yaron has led clinical trials in the US, Europe and Israel as well as worked with CRO’s all over the world.
Christopher Gondi, PhD
Dr. Gondi is an Associate Professor – Departments of Medicine, Surgery and Pathology at the University of Illinois, College of Medicine, Peoria. He is a professor of cancer biology and has extensive experience dealing with brain tumors and pancreatic cancer, for which the survival rates are very low.
Christopher seeks to investigate and advance the therapeutic benefits of psychedelic-therapy for those facing mental and emotional struggles at the end of life, and how these compounds can be used to effectively treat substance-use disorder.
Ruth Chun, M.A., J.D.
Ruth Chun is an independent director and member of the audit committee.
Ms. Chun is corporate commercial lawyer focused on advising regulated businesses in the cannabis, psychedelics and technology industries. Prior to founding Chun Law Professional Corporation, she was the general counsel and corporate secretary for Newstrike Brands Ltd. / Up Cannabis Inc. and senior legal counsel at HEXO Corp. through its acquisition of Newstrike in an all share deal valued at $346 million. Ms. Chun joined Newstrike in February 2017 and was involved in all significant corporate activity including a successful TSXV listing, debt and equity financings (exceeding $140 million), M&A, regulatory matters and government relations. She is regularly called upon as a speaker, industry expert and guest lecturer at various colleges and universities.
Ms. Chun currently serves on several boards and is the chairperson of SAVIS of Halton. She served as the first female executive at a leading insurer in southern Africa as the head of legal and compliance and was a partner at Africa’s largest law firm. Previously, she chaired Rio Tinto’s pension fund for Rössing Uranium Mine and was a trustee of the Alexander Forbes umbrella group of funds. She received an Hon BA (Trinity College), MA from the University of Toronto and Juris Doctor from Queens University. She is called to the bar in Ontario, New York and Namibia.
Corporate Finance / M&As
Founded in 1966, DuMoulin Black has counselled hundreds of companies on the successful structuring and coordination of their corporate finance requirements and M&A needs. Having a strong relationship with investors, regulators, stock exchanges, underwriters and various industry professionals, DuMoulin Black is a trusted and effective legal partner with the track record and reputation required to navigate the modern day legal and corporate environment.
Patents & IP
Zuber Lawler is one of the most selective law firms in the United States, with 40-plus attorneys representing clients throughout the world from offices in Chicago, Los Angeles, New York, and Silicon Valley. Our clients include more than 15 Fortune 500 clients, as well as funds and government entities. Primary practice areas include IP, regulatory work, class actions and M&A, both domestically and across languages and borders throughout the world. Zuber Lawler has attorneys trained in both common and civil law systems.
Professor Matthew W. Johnson, PhD
Matthew Johnson is a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, and an expert on psychoactive drugs and addiction. Matthew earned his Ph.D. in experimental psychology at the University of Vermont in 2004, has published over 110 peer-reviewed articles, and in 2008 published his psychedelic safety guidelines, which helped to resurrect and guide forthcoming psychedelic research.
Dr. Johnson has been interviewed widely by media; including 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, NPR, and Fox Business News.
Robin Carhart-Harris, PhD
Robin Heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College, London, where he has designed a number of functional brain imaging studies with psychedelic compounds, plus a clinical trial of psilocybin targeting treatment resistant depression. Robin has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016.
Dr Carhart-Harris obtained his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. He has an honorary position at the University of Oxford.
Dr. Dennis McKenna
Dennis is an American ethnopharmacologist, research pharmacognosist, lecturer and author. He is the brother of well-known psychedelics proponent Terence McKenna and is a founding board member and the director of ethnopharmacology at the Heffter Research Institute. As an advisor to Entheon, he brings with him decades of research and insight.
Dr. Michael Walker
Dr. Walker received his pharmacology training at the University of London which included a period of drug discovery training at Pfizer Ltd., (UK). Dr. Walker’s main focus has been in the discovery of drugs, both naturally occurring and synthetic, and he has developed an expertise in traversing the path to successful drug discovery.
Over the past 25 years, Dr. Walker was the founder or co-founder of eight different drug discovery companies, both public and private, including Cardiome Pharma (TSX:COM) in Canada and Verona Pharma Ltd. in London.
Christopher Timmermann, PhD
Christopher is a psychologist educated at the Catholic University of Chile with a Masters in Neuroscience and Neuropsychological Therapy from the University of Bologna. Christopher received his PhD at the Centre for Psychedelic Research / Psychedelic Research Group, based at The Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL). His research focuses on the effects of DMT in the human brain.
Malin Vedøy Uthaug, PhD
Completing her PhD at the department of Neuropsychology and Psychopharmacology, at the faculty of Psychology and Neuroscience at Maastricht University, The Netherlands, Malin investigated the short-term and long-term effects of ayahuasca and 5-MeO-DMT in naturalistic setting. Malin is currently working as a Research Assistant at The Centre for Psychedelic Research, at Imperial College London, led by Dr. Robin Carhart-Harris. Here she is investigating the effects of 5-MeO-DMT on mental health related variables, brain activity and consciousness.
Kenneth W. Tupper, PhD
Advisor of Ethics
Kenneth served as an Adjunct Professor in the School of Population and Public Health at the University of British Columbia, and has been active in the field of psychedelic studies for more than fourteen years.
Kenneth is also a member of the Clinical & Scientific Advisory Board of the Multidisciplinary Association for Psychedelic Studies – Canada (MAPS-Canada) and is on the Advisory Board of the Wasiwaska Research Centre in Brazil.
Special Advisor of Data Science and Regulatory Affairs
Ms. Maher has served as an executive and consultant for major pharmaceutical and information technology companies, including IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is currently SVP, Chief Information Officer, North America of Kyowa Kirin International plc., and joins Entheon as its Special Advisor of Data Science and Regulatory Affairs.
Ms. Maher will be consulting on the development and implementation of Entheon’s data management systems for the collection, organization and analysis of data from upcoming pre-clinical and clinical trials, partnership initiatives, private clinic partnerships, and various technological initiatives. In addition, Ms. Maher will inform the Company of best practices for the design and implementation of security measures as they relate to the Company’s data program, while also informing regulatory strategy and relationship as it relates to advancing conversations and applications with Health Canada, the FDA and EMA regulatory authorities.
Click Here To Expand And Read
April 6, 2021
Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test
March 3, 2021
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
FEBRUARY 24, 2021
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
FEBRUARY 22, 2021
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study
FEBRUARY 16, 2021
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development
FEBRUARY 2, 2021
Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments
JANUARY 22, 2021
Entheon Biomedical to be Included in First North American Psychedelic ETF
JANUARY 19, 2021
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
JANUARY 14, 2021
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
JANUARY 12, 2021
Entheon Biomedical Engages Star Finance GmbH for Investor Relations
JANUARY 11, 2021
Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor
JANUARY 04, 2021
Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC
DECEMBER 25, 2020
Entheon Biomedical Closes Private Placement
DECEMBER 18, 2020
Entheon Biomedical Announces Private Placement
DECEMBER 09, 2020
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
DECEMBER 04, 2020
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
DECEMBER 01, 2020
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
NOVEMBER 12, 2020
Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange
NOVEMBER 05, 2020
Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
OCTOBER 28, 2020
MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp.
MAY 07, 2020
Entheon Biomedical Announces Private Placement to Begin Pre-clinical Trials with Psychedelic Compounds DMT & 5 MEO DMT